The price of bulk drug at which the above prices of formulations were fixed is not available. However the notified price of Phenobarbitone at that time was Rs. 580.16 per kg. Company-wise import of bulk drug is not monitored by the Government. Further, Imports Statistics with regard to Phenobarbitone for the year 1991 is also not available.

(e) As per available information, Phenobarbitone/Sodium is manufactured by M/s. IDPL in the country. This company has reported production of 10.76, 5.12 and 2.58 tonnes of this bulk drug during 1987-88, 1988-89 and 1989-90 respectively.

(f) There is no ceiling pack of formulation based on bulk drug Phenobarbitone Sodium and as such no price has been notified.

Consumption of Raw Materials for the Productions of Bulk Drugs.

3112. SHRI RAJNI RANJAN SAHU: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1650 given in the Raja Sabha on 12th September, 1991 and state:

(a) whether it is a fact Form 6 calls for the information of Consumption of imported and indigenous raw materials separately consumed for the production of Bulk drugs;

(b) whether it is also a fact that similar information is called for from the manufacture of formulations; and

(c) if so, what was the quantity of imported raw material bulk drugs and indigenous raw materials and bulk drugs consumed by each of the multinational Drug Companies during the last three years, year-wise in value?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) No, Sir.

(c) Information regarding indigenous and imported bulk drugs consumed has been prescribed in Form—6. As already answered in reply to Unstarred Question No. 1650 dated 12-9-91, the response to the industry to submission of Form 6 has been quite lukewarm. As such, the details asked for are not available.

Liabilities shown by Multinational Drug Companies

3113. DR. RATNAKAR PANDEY: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 683 given in the Rajya Sabha on the 28th November, 1991 and state:

(a) what are the names of companies out of the nine multinational drug companies referred who have shown liabilities in their balance sheets;

(b) what are the details of liabilities and what is the amount indicated by each company;

(c) what are the names of the companies against whom amount due under DPEA is to be recovered and what are the details of amount due against each;

(d) whether it is a fact that Government have come across instances of overcharging, over invoicing in imports and violations of orders and acts by these companies; and

(e) if so, the details thereof and action taken against each?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) To the extent information is available M|s. Glaxo and M|s. Merind had shown the liability in their balance-sheets.

(b) and (c) As per available information, M/s. Glaxo did make a provision of Rs. 30.86 crores in its accounts for 1987-88 as its liability for DPEA claims which, in